RECIST underestimates benefit of pembrolizumab in subset of melanoma patients

Certain patients with advanced melanoma treated with pembrolizumab had unique response patterns, such as early or delayed tumor pseudoprogression, and Response Evaluation Criteria in Solid Tumors (RECIST) criteria might underestimate the immunotherapy benefit in this subset. Among 592 patients...
Source: Skin and Allergy News - Category: Dermatology Source Type: news